DLBCL | Clinical

Not All Patients With Relapsed DLBCL Referred for CAR T in Community Setting

December 03, 2020

In an interview with Targeted Oncology, Ajeet Gajra, MD, FACP, vice president, Cardinal Health, discussed the ongoing challenges community oncologists face with prescribing CAR T-cell therapy to patients with relapsed/refractory diffuse large B-cell lymphoma.

Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCL

December 01, 2020

During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.

In Patients With Relapsed/Refractory DLBCL, Tafasitamab/Lenalidomide Combo Shines

November 26, 2020

Kami J. Maddocks, MD, discussed the efficacy and safety of tafasitamab in combination with lenalidomide as treatment of a 74-year-old man with diffuse large B-cell lymphoma. The treatment option was discussed with a group of oncologists during a Targeted Oncology Case Based Peer Perspective event.

Biomarker for Immune Response Identified in Relapsed/Refractory DLBCL

November 14, 2020

In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study demonstrated that certain gene expressions are associated with response to DPX-Survivac plus pembrolizumab and intermittent, low-dose cyclophosphamide.

Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies

November 05, 2020

In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.